$AUPH News

Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Settles Teva Patent Litigation, Protecting Voclosporin Exclusivity In U.S. Until December 2036 And Affirming Validity Of Key Patents Through 2037

Aurinia Pharmaceuticals Doubles Down On Its Pipeline

RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $16

Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $323.065M Est

Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M Estimate

Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Screens as Strong Candidate Based on Minervini Trend Template and High Growth Momentum Rating

A Fresh Look At Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Consolidation

Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow

Aurinia Pharmaceuticals' New Analysis Of Aurora 1 Phase 3 Study Of Lupkynis For Lupus Nephritis Shows Statistically Significant 53% Reduction In The Risk Of Renal-related Event Or Death

Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks Transcript

Chief Executive Officer Of Aurinia Pharmaceuticals Makes $12.46M Buy

TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.

Tang Capital Raises Aurinia Pharmaceuticals Holding to 10%

Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences

We Believe Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings Are A Poor Guide For Its Profitability